Nektar Therapeutics Reviews

3.1
28 Reviews
Rating Trends
Recommend to a friend
Approve of CEO
Nektar Therapeutics President, CEO, and Director Howard W. Robin
Howard W. Robin
21 Ratings
  • GREAT EXPERIENCE

    • Comp & Benefits
    • Work/Life Balance
    • Senior Management
    • Culture & Values
    • Career Opportunities
    Former Employee - Manager in San Francisco, CA
    Former Employee - Manager in San Francisco, CA

    I worked at Nektar Therapeutics full-time (more than a year)

    Recommends
    Positive Outlook
    No opinion of CEO
    Recommends
    Positive Outlook
    No opinion of CEO

    Pros

    For a small/mid company good benefits and nice environment to work in. Good processes and systems in place. Company which already has a number of licensed products ensuring is not going belly up any time soon.

    Cons

    Benefits could be a bit better. They could do a better job with 401K. Salaries nothing to write home about it

    Advice to Management

    A bit of too much micro management internally and with outsourcing vendors

Nektar Therapeutics Interviews

Interview Experience

Interview Experience

75%
12%
12%

Getting an Interview

Getting an Interview

65%
11%
11%

Interview Difficulty

2.9
Average

Interview Difficulty

Hard

Average

Easy
  1.  

    QA Interview

    Accepted Offer
    Positive Experience
    Average Interview
    Accepted Offer
    Positive Experience
    Average Interview

    Application

    I applied online. The process took 3+ monthsinterviewed at Nektar Therapeutics (San Francisco, CA).

    Interview

    Good process, and very thorough; but took way too long to finally get an offer and start date.

    Interview Questions

    Negotiation

    Rigid, inflexible

Nektar Therapeutics Awards & Accolades

Something missing? Add an award
Best Places to Work for Commuters, National Center for Transit Research at USF, 2012

Additional Info

Unlock Profile
Website www.nektar.com
Headquarters San Francisco, CA
Size 150 to 499 Employees
Founded 1990
Type Company - Public (NKTR)
Industry Biotech & Pharmaceuticals
Revenue $100 to $500 million (USD) per year

Nektar Therapeutics has pegged its fortunes to making drugs more effective. The clinical-stage drug development firm uses its PEGylation technology, (based upon polyethylene glycol) to improve the delivery and efficacy of existing drugs. Nektar's pipeline is focused on anti-infectives and anti-virals, immunology, oncology, and pain treatments. Its lead candidate NKTR-118 (which it is developing in collaboration with AstraZeneca) is being tested as a treatment for opioid-induced constipation. It also maintains a handful of preclinical candidates. Nektar receives royalties... More

Work at Nektar Therapeutics? Share Your Experiences

Nektar Therapeutics

 
Click to Rate
or